sotalol has been researched along with Cardiac Arrest, Sudden in 30 studies
Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.
sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We compared the ability of a new amiodarone-like agent, SR 33589, with that of amiodarone, D,L-sotalol, and lignocaine to reduce the incidence of ventricular fibrillation (VF) and associated arrhythmias caused by acute coronary artery occlusion in anesthetized pigs." | 7.69 | Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs. ( Chatelain, P; Finance, O; Manning, A, 1995) |
| "Sotalol is a betablocker with additional antiarrythmic properties." | 5.30 | [Sotalol--atrial fibrillation, reduced renal function and sudden death]. ( Bathen, J; Madsen, S, 1998) |
| "Six patients with short QT syndrome, five of whom had received an implantable cardioverter-defibrillator (ICD) and one child, were tested with different antiarrhythmic drugs, including flecainide, sotalol, ibutilide, and hydroquinidine, to determine whether they could prolong the QT interval into the normal range and thus prevent symptoms and arrhythmia recurrences." | 5.11 | Short QT syndrome: pharmacological treatment. ( Antzelevitch, C; Bianchi, F; Borggrefe, M; Brugada, R; Calò, L; Gaita, F; Giustetto, C; Haissaguerre, M; Schimpf, R; Wolpert, C, 2004) |
| " A total of 152 patients with remote myocardial infarction and documented ventricular tachycardia (VT) or ventricular fibrillation (VF) underwent coronary angiography and programmed ventricular stimulation before and after oral administration of d,l-sotalol (240-640 mg/day)." | 3.70 | Infarct related artery patency: relation to serial electropharmacological studies and outcome in patients with previous myocardial infarction and ventricular tachyarrhythmias. ( Borggrefe, M; Breithardt, G; Haverkamp, W; Hoppe, UC, 2000) |
| "We compared the ability of a new amiodarone-like agent, SR 33589, with that of amiodarone, D,L-sotalol, and lignocaine to reduce the incidence of ventricular fibrillation (VF) and associated arrhythmias caused by acute coronary artery occlusion in anesthetized pigs." | 3.69 | Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs. ( Chatelain, P; Finance, O; Manning, A, 1995) |
| "Sudden cardiac death was observed in 16 patients, 8 patients in each group." | 2.72 | Determinants of sudden cardiac death in patients with persistent atrial fibrillation in the rate control versus electrical cardioversion (RACE) study. ( Crijns, HJ; Hagens, VE; Rienstra, M; Van Gelder, IC; Van Veldhuisen, DJ, 2006) |
| "In patients prone to sudden cardiac death, there is a reduction in TWA amplitude following the administration of antiadrenergic drugs." | 2.70 | Effect of metoprolol and d,l-sotalol on microvolt-level T-wave alternans. Results of a prospective, double-blind, randomized study. ( Grönefeld, G; Hohnloser, SH; Klingenheben, T; Li, YG, 2001) |
| "Sotalol was significantly more efficacious in preventing recurrences, arrhythmic mortality, cardiac mortality, and total mortality than the other agents and it was better tolerated." | 2.67 | Results of Holter ECG guided therapy for ventricular arrhythmias: the ESVEM trial. ( Lazzara, R, 1994) |
| "Sudden cardiac death is a prominent feature of the natural history of heart disease." | 2.41 | Overview of randomized trials of antiarrhythmic drugs and devices for the prevention of sudden cardiac death. ( Heidenreich, PA; Hlatky, MA; Keeffe, B; McDonald, KM, 2002) |
| "Sotalol has not been widely studied in postinfarct patients; one trial indicated that the drug did reduce total mortality but the difference did not reach statistical significance." | 2.39 | Expanding indications for the use of Class III agents in patients at high risk for sudden death. ( Singh, BN, 1995) |
| "sustained ventricular tachycardia, ventricular fibrillation, aborted sudden cardiac death) are changing." | 2.39 | [Pharmacologic therapy of ventricular tachyarrhythmias: value of class III anti-arrhythmia drugs]. ( Block, M; Böcker, D; Borggrefe, M; Breithardt, G; Haverkamp, W, 1996) |
| "Amiodarone has been demonstrated to be an important and effective antiarrhythmic agent, as has sotalol." | 2.38 | Empiric use of amiodarone and sotalol. ( Nora, M; Zipes, DP, 1993) |
| "Amiodarone and sotalol were found to have a neutral effect on survival." | 1.33 | Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defibrillators. ( Ho, AT; Pai, RG; Pai, SM; Timothy, P, 2005) |
| "Cardiac mortality and sudden cardiac death rates also were higher in group 3 patients." | 1.32 | Clinical usefulness of electrophysiologic testing in patients with ventricular tachycardia and chronic chagasic cardiomyopathy treated with amiodarone or sotalol. ( de Paola, AA; Fenelon, G; Friedman, PA; Leite, LR; Silva, GG; Simoes, A, 2003) |
| "Arrhythmogenic right ventricular dysplasia is an inherited, progressive condition." | 1.31 | Arrhythmogenic right ventricular dysplasia. An illustrated review highlighting developments in the diagnosis and management of this potentially fatal condition. ( Fisher, NG; Gilbert, TJ, 2000) |
| "Sotalol is a betablocker with additional antiarrythmic properties." | 1.30 | [Sotalol--atrial fibrillation, reduced renal function and sudden death]. ( Bathen, J; Madsen, S, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (46.67) | 18.2507 |
| 2000's | 13 (43.33) | 29.6817 |
| 2010's | 3 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pokorney, SD | 1 |
| Mi, X | 1 |
| Hammill, BG | 1 |
| Allen LaPointe, NM | 1 |
| Curtis, LH | 1 |
| Al-Khatib, SM | 1 |
| Brugada, J | 1 |
| Gussak, I | 1 |
| Brugada, P | 1 |
| Ito, S | 1 |
| Stout, KK | 1 |
| Robinson, MR | 1 |
| Heidenreich, PA | 1 |
| Keeffe, B | 1 |
| McDonald, KM | 1 |
| Hlatky, MA | 1 |
| Leite, LR | 1 |
| Fenelon, G | 1 |
| Simoes, A | 1 |
| Silva, GG | 1 |
| Friedman, PA | 1 |
| de Paola, AA | 1 |
| Exner, DV | 1 |
| Klein, GJ | 1 |
| Pratt, CM | 1 |
| Gaita, F | 1 |
| Giustetto, C | 1 |
| Bianchi, F | 1 |
| Schimpf, R | 1 |
| Haissaguerre, M | 1 |
| Calò, L | 1 |
| Brugada, R | 1 |
| Antzelevitch, C | 1 |
| Borggrefe, M | 3 |
| Wolpert, C | 1 |
| Ho, AT | 1 |
| Pai, SM | 1 |
| Timothy, P | 1 |
| Pai, RG | 1 |
| Binder, WD | 1 |
| Fifer, MA | 1 |
| King, ME | 1 |
| Stone, JR | 1 |
| Hagens, VE | 1 |
| Rienstra, M | 1 |
| Van Veldhuisen, DJ | 1 |
| Crijns, HJ | 1 |
| Van Gelder, IC | 1 |
| Melacini, P | 1 |
| Maron, BJ | 1 |
| Bobbo, F | 1 |
| Basso, C | 1 |
| Tokajuk, B | 1 |
| Zucchetto, M | 1 |
| Thiene, G | 1 |
| Iliceto, S | 1 |
| Lazzara, R | 1 |
| Raza, A | 1 |
| Nora, M | 1 |
| Zipes, DP | 1 |
| Singh, BN | 1 |
| Finance, O | 1 |
| Manning, A | 1 |
| Chatelain, P | 1 |
| Cobbe, SM | 1 |
| Haverkamp, W | 2 |
| Block, M | 1 |
| Böcker, D | 1 |
| Breithardt, G | 2 |
| Hohnloser, SH | 2 |
| McAlister, FA | 1 |
| Teo, KK | 1 |
| Giorgberidze, I | 1 |
| Saksena, S | 1 |
| Krol, RB | 1 |
| Munsif, AN | 1 |
| Kolettis, T | 1 |
| Mathew, P | 1 |
| Varanasi, S | 1 |
| Prakash, A | 1 |
| Delfaut, P | 1 |
| Lewis, CB | 1 |
| Fogoros, RN | 1 |
| Bathen, J | 1 |
| Madsen, S | 1 |
| Ferrari, R | 1 |
| Cinca, J | 1 |
| Marber, M | 1 |
| Hoppe, UC | 1 |
| Fisher, NG | 1 |
| Gilbert, TJ | 1 |
| Cooley, R | 1 |
| Akhtar, M | 1 |
| Sra, J | 1 |
| Mérot, J | 1 |
| Probst, V | 1 |
| Debailleul, M | 1 |
| Gerlach, U | 1 |
| Moise, NS | 1 |
| Le Marec, H | 1 |
| Charpentier, F | 1 |
| Klingenheben, T | 1 |
| Grönefeld, G | 1 |
| Li, YG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000518] | Phase 3 | 0 participants | Interventional | 1985-07-31 | Completed | ||
| [NCT00000531] | Phase 3 | 0 participants | Interventional | 1992-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for sotalol and Cardiac Arrest, Sudden
| Article | Year |
|---|---|
Overview of randomized trials of antiarrhythmic drugs and devices for the prevention of sudden cardiac death.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Femal | 2002 |
Pure class III agents for prevention of sudden cardiac death.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Comorbidity; Death, Sudden, C | 2003 |
Empiric use of amiodarone and sotalol.
Topics: Amiodarone; Cardiomyopathy, Hypertrophic; Coronary Disease; Death, Sudden, Cardiac; Heart Diseases; | 1993 |
Expanding indications for the use of Class III agents in patients at high risk for sudden death.
Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Death, Sudden, Cardiac; Humans; Risk F | 1995 |
[Pharmacologic therapy of ventricular tachyarrhythmias: value of class III anti-arrhythmia drugs].
Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Combined Modality Therapy; Death, Sudd | 1996 |
[Drug therapy of ventricular arrhythmias].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Electrocardiography; Hu | 1997 |
Antiarrhythmic therapies for the prevention of sudden cardiac death.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Artery Bypass; Death, Sudden, Car | 1997 |
Sudden cardiac death: who needs an implantable cardioverter-defibrillator and who needs antiarrhythmic drugs?
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Humans; Sec | 1999 |
Is primary antiarrhythmic drug therapy for ventricular arrhythmias obsolete?
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Humans; Ran | 1999 |
5 trials available for sotalol and Cardiac Arrest, Sudden
| Article | Year |
|---|---|
Short QT syndrome: pharmacological treatment.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Child; Death, Sudden, Cardiac | 2004 |
Determinants of sudden cardiac death in patients with persistent atrial fibrillation in the rate control versus electrical cardioversion (RACE) study.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2006 |
Results of Holter ECG guided therapy for ventricular arrhythmias: the ESVEM trial.
Topics: Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Death, Sudden, Cardiac; Electrocardiography, Amb | 1994 |
Risk stratification and clinical outcome of minimally symptomatic and asymptomatic patients with nonsustained ventricular tachycardia and coronary disease: a prospective single-center study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Confounding Factors, Epidemiologic; Coronary Disease; Deat | 1997 |
Effect of metoprolol and d,l-sotalol on microvolt-level T-wave alternans. Results of a prospective, double-blind, randomized study.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Cause of Death; Coronary Disease; Death, | 2001 |
16 other studies available for sotalol and Cardiac Arrest, Sudden
| Article | Year |
|---|---|
Use of Antiarrhythmic Medications in Medicare Part D Patients With an Implantable Cardioverter-Defibrillator and Ventricular Tachycardia.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Databases, | 2017 |
Short QT syndrome: a predictable story.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Electrocardiography; Female; H | 2014 |
Non-sustained ventricular tachycardia in a pregnant woman with repaired Tetralogy of Fallot: A challenging case.
Topics: Adult; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Female; Humans; | 2016 |
Clinical usefulness of electrophysiologic testing in patients with ventricular tachycardia and chronic chagasic cardiomyopathy treated with amiodarone or sotalol.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Brazil; Chagas Cardiomyopathy; Death, Sudden, Cardiac; Dr | 2003 |
Do we need a randomized trial of defibrillator therapy in every subset of patients with increased risk of sudden death?
Topics: Amiodarone; Anti-Arrhythmia Agents; Chagas Cardiomyopathy; Death, Sudden, Cardiac; Defibrillators, I | 2003 |
Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defibrillators.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Combined Moda | 2005 |
Case records of the Massachusetts General Hospital. Case 26-2005. A 48-year-old man with sudden loss of consciousness while jogging.
Topics: Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Death, Sudden, Cardiac; Diagnosis, Differentia | 2005 |
Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyop | 2007 |
Beta-receptor blockade in preventing sudden death.
Topics: Adrenergic beta-Antagonists; Atenolol; Death, Sudden, Cardiac; Humans; Metoprolol; Practolol; Sotalo | 1993 |
Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs.
Topics: Amiodarone; Analysis of Variance; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzofurans | 1995 |
Class III Antiarrhythmics: put to the SWORD?
Topics: Action Potentials; Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Huma | 1996 |
Why the antiarrhythmics versus implantable defibrillator (AVID) trial sets the wrong precedent.
Topics: Amiodarone; Anti-Arrhythmia Agents; Bias; Death, Sudden, Cardiac; Defibrillators, Implantable; Ethic | 1997 |
[Sotalol--atrial fibrillation, reduced renal function and sudden death].
Topics: Acute Kidney Injury; Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Death, Sudden, Cardiac; | 1998 |
Infarct related artery patency: relation to serial electropharmacological studies and outcome in patients with previous myocardial infarction and ventricular tachyarrhythmias.
Topics: Aged; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Coronary Angiography; Death, Sudden, Cardi | 2000 |
Arrhythmogenic right ventricular dysplasia. An illustrated review highlighting developments in the diagnosis and management of this potentially fatal condition.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventric | 2000 |
Electropharmacological characterization of cardiac repolarization in German shepherd dogs with an inherited syndrome of sudden death: abnormal response to potassium channel blockers.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chromans; Death, Sudden, Cardiac; Dog Disease | 2000 |